Galaxy88
2021-11-29
Ok
Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":600546606,"tweetId":"600546606","gmtCreate":1638179062439,"gmtModify":1638179842160,"author":{"id":4091842669394280,"idStr":"4091842669394280","authorId":4091842669394280,"authorIdStr":"4091842669394280","name":"Galaxy88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600546606","repostId":1106015985,"repostType":4,"repost":{"id":"1106015985","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohunote.com/m/news/1106015985?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading<blockquote>Moderna 股价在盘前交易中飙升 8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna 股价在盘前交易中飙升 8%，因为该公司表示奥密克戎的新型 covid-19 疫苗可能会在 2022 年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官Paul Burton表示，他怀疑新的奥密克戎冠状病毒变种可能会躲过当前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11 月 28 日）在 BBC 安德鲁·马尔秀节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到 2022 年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA 疫苗（Moderna 平台）的非凡之处在于我们可以非常快速地移动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>上周四美国感恩节早些时候，在奥密克戎变种病毒的消息传开后，这家总部位于马萨诸塞州剑桥的生物技术公司动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人接种疫苗的时间，目前最好的建议是接种当前的 Covid-19 疫苗之一。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的武器库中有很多工具可以对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>上周五，由于担心这可能会加剧北半球冬季新冠肺炎疫情激增并破坏全球经济复苏，全球市场掀起了一波避险情绪，这种情绪在周日中东开盘时仍在继续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在快速测试当前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自 2021 年初以来，Moderna 已推进一项全面战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在 60 至 90 天内将新候选药物推进临床试验。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1103,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/600546606"}
精彩评论